SCHEMBL4258090

SCHEMBL4258090

COC(=O)c1ccncc1-c1ccc(F)cc1C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.52
KDM4E B2RXH2 1/20 0.49
ALDH1A1 P00352 1/20 0.49
GLA P06280 1/20 0.49
GAA P10253 1/20 0.49
CYP46A1 Q9Y6A2 1/20 0.47
GPBAR1 Q8TDU6 2/20 0.46
SLC6A4 P31645 1/20 0.43
SLC6A3 Q01959 1/20 0.43
SLC2A1 P11166 1/20 0.43
POLQ O75417 1/20 0.43
CYP11B2 P19099 1/20 0.43
LMNA P02545 1/20 0.40
ALPL P05186 1/20 0.40
NOTUM Q6P988 1/20 0.40
NPC1 O15118 1/20 0.40
CASP3 P42574 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
SENP8 Q96LD8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4251045 0.88 L3MBTL1 (0.53) L3MBTL1KDM4EALDH1A1GLAGAA
SCHEMBL30292704 0.83 L3MBTL1 (0.51) L3MBTL1KDM4EALDH1A1GLAGAA
SCHEMBL30292707 0.83 L3MBTL1 (0.51) L3MBTL1KDM4EALDH1A1GLAGAA
SCHEMBL29276904 0.83 L3MBTL1 (0.51) L3MBTL1KDM4EALDH1A1GLAGAA
SCHEMBL21056662 0.80 KDM4E (0.54) L3MBTL1KDM4EALDH1A1GLAGAA
SCHEMBL4251420 0.80 SLC6A3 (0.63) L3MBTL1KDM4EALDH1A1GLAGAA
SCHEMBL27170874 0.79 L3MBTL1 (0.50) L3MBTL1KDM4EALDH1A1GLAGAA
SCHEMBL21056912 0.79 ALDH1A1 (0.53) L3MBTL1KDM4EALDH1A1GLAGAA
SCHEMBL21056841 0.76 TGFBR1 (0.56) L3MBTL1KDM4EALDH1A1GLAGAA
SCHEMBL31083379 0.76 ALDH1A1 (0.49) L3MBTL1KDM4EALDH1A1GLAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090005355-A1 Piperidine Compound and Process for Preparing the Same TANABE SEIYAKU CO., LTD. (JP) 2009-01-01 US disclosed
US-20090005355-A1 Piperidine Compound and Process for Preparing the Same TANABE SEIYAKU CO., LTD. (JP) 2009-01-01 US disclosed
US-20090005355-A1 Piperidine Compound and Process for Preparing the Same TANABE SEIYAKU CO., LTD. (JP) 2009-01-01 US disclosed
US-20070244158-A1 Piperdine Compound and Process for Preparing the Same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-10-18 US disclosed
US-20070244158-A1 Piperdine Compound and Process for Preparing the Same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-10-18 US disclosed
US-20070244158-A1 Piperdine Compound and Process for Preparing the Same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-10-18 US disclosed
EP-1789389-A1 PIPERIDINE COMPOUND AND PROCESS FOR PREPARING THE SAME TANABE SEIYAKU CO., LTD. (JP) 2007-05-30 EP disclosed
EP-1765780-A1 PIPERIDINE COMPOUND AND PROCESS FOR PREPARING THE SAME TANABE SEIYAKU CO., LTD. (JP) 2007-03-28 EP disclosed
WO-2006030984-A1 PIPERIDINE COMPOUND AND PROCESS FOR PREPARING THE SAME TANABE SEIYAKU CO., LTD. (JP) 2006-03-23 WO disclosed
WO-2006004195-A1 PIPERIDINE COMPOUND AND PROCESS FOR PREPARING THE SAME TANABE SEIYAKU CO., LTD. (JP) 2006-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244158-A1 Piperdine Compound and Process for Preparing the Same AVPR1B, PRLHR, HRH4 L3MBTL1 4532/4885KDM4E 1740/4885ALDH1A1 2744/4885
US-20090005355-A1 Piperidine Compound and Process for Preparing the Same AVPR1B, HRH4, PRLHR L3MBTL1 4431/4885KDM4E 1451/4885ALDH1A1 2868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.